Overview

• Amsterdam UMC researchers published phase one trial results in *Science*, demonstrating targeted immune activation using the Env trimer GT1.1 immunogen.
• The trial involved 47 participants who received either a high dose, low dose, or placebo, with results confirming precise targeting of B-cell populations.
• The vaccine aims to induce broadly neutralizing antibodies, a critical step toward combating HIV's diverse strains.
• HIV remains a global health crisis, with 40 million people infected worldwide and over 600,000 deaths annually, two-thirds of which occur in Africa.
• Researchers plan follow-up studies to further develop the vaccine, focusing on stimulating the targeted cells to produce broadly neutralizing antibodies.